All News
Mitigating Immunogenicity When Using Uricase Therapies as ULT
ACR20 convergence highlights a shift in gout management and uric acid lowering therapy (ULT). The new biologics pegdriticase and pegloticase are associated with risk of immunogenicity and loss of biological effects.
Read Article
Should ARBs be adjunct Rx in GCA?
Plausible target:
- previous pharmacoepi
- ATII expressed in GCA inflamm lesions
- ATII induced pro-inflamm in PBMC/co-cultured VSMC
- steroids modulate ATII expression in GCA TA ex vivo
Maybe worth testing?
Cid et al #ACR20 ABST0510 @RheumNow https://t.co/mNNzZVYe7g
David Liew drdavidliew ( View Tweet)
@RheumNow #acr20 abs0622 infection induced MPO anca vasc: most common triggers viruses(35.2%), mycobacterial (29.4%)& bacterial inf (29.4%). Onset 3 mo post inf. (70.5%) renal involvement, w/ biopsy-proven GN in 53%. 17.6%died. Rx steroids+abx, CYC in 47%.
Olga Petryna DrPetryna ( View Tweet)
We have great options all around! Both are efficacious in biologic (TNFi) failures for RA patients.
Comparative Clinical Efficacy of Sarilumab versus Upadacitinib over 12 Weeks: Matching-Adjusted Indirect Comparison Analysis Abst#0827 #ACR20 @RheumNow
https://t.co/1SsL9qLJD3
k dao KDAO2011 ( View Tweet)
Is diet important in gout control? #ACR20 @rheumnow
Richard Conway RichardPAConway ( View Tweet)
EQUATOR2 52wk extension trial - Filgotinib on enthesitis in PsA pts
1️⃣Clinical resolution of enthesitis at 52wks 77% by LEI and SPARCC
2️⃣Pts who did not respond by wk 16➡️77% and 81% resolution enthesitis by LEI and SPARCC
@RheumNow #ACR20 Abs#0910 https://t.co/mCe32rrAcc
Robert B Chao, MD doctorRBC ( View Tweet)
@RheumNow #acr20 abs0665 claim based database stdy of pegloticase/immunomodulation coadministration trends: use of co-immunomodulation ⬆️ from 1.2%-3.9% 2015- 2018 to 15.0% in 2019. 86%start immunomodulator within 30 days of first peg infusion. MTX most commonly used
Olga Petryna DrPetryna ( View Tweet)
When you counsel patients w/RA, do you warn them that during times of dz flare, their ability to drive may be affected? ...maybe you should based on Abstr#0198
#ACR20 @rheumnow
k dao KDAO2011 ( View Tweet)
@RheumNow #ACR20 abs0710 early biologic therapy (BT) in JIA: Early BT=better outcome ( 81.8% on TNFi). BT start after 7,5mo from Dx correlates w/higher probability of active disease at 2 yrs (S=0,67 E=0,63). In active group at 2y 75% arthritis, 16,7% uveitis& 8,3% both. #ACRbest
Olga Petryna DrPetryna ( View Tweet)
Nice insights into RA-ILD from @jeffsparks:
- assoc (in Medicare): male, smoker, asthma/COPD, b/tsDMARDs, steroids
- mortality risk? Yes, esp resp (sdHR 4.4), cancer
- ACPA/lung inflamm related to RA-ILD? Yes, esp anti-filaggrin (aOR 3.08/log unit)
#ACR20 ABST0489/0490 @RheumNow https://t.co/DGkNNPOcbd
David Liew drdavidliew ( View Tweet)
@Janetbirdope @RheumNow @CRASCRRheum This study is a follow-on to an existing body of evidence re: vitamin K-dependent proteins ("Gla" proteins) in #OA, as well as warfarin VK antagonist effects, and agnostic discovery in a GWAS. The findings hold including in studies unrelated to access to care and a small RCT.
Tuhina Neogi, MD, PhD Tuhina_Neogi ( View Tweet)
Be sure to check this session with @CCalabreseDO and Dr. Gordon Lam on the role of IL6 in inflammation, RA, and CRS at 2 pm EST today! #ACR20 @RheumNow https://t.co/c4oX1tNeId
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Dr Sammy Zakaria said we need close communication with cardiologist in myocarditis related to myositis. #ACR20 @RheumNow https://t.co/kTAZKWpw0S
Sole RetamozoSole ( View Tweet)
Did you know? ADA was initially named "Eric" after the fierce soccer star "Eric Daniel Pierre Cantona"! @RheumNow #ACR20 https://t.co/5WvA5Ov3Fu
sheila RHEUMarampa ( View Tweet)
HCQ might decrease risk for NAFLD!
Restrospective study of 5600 pts noted patients on HCQ (despite having more metabolic syndrome, HTN, DM) had 24% less incidence of NAFLD compared to pts not on HCQ
Abstr#0177 #ACR20 @rheumnow
https://t.co/ZoK2aC0ZQR
k dao KDAO2011 ( View Tweet)
Myositis:getting to the Heart. #ACR20 Prof Chung @RheumNow https://t.co/pj9rzmRgyx
Sole RetamozoSole ( View Tweet)
Coding 101 pearls! Under coding is considered fraud per Dr. Vladimir Liarski @vladml @RheumNow #ACR20 https://t.co/idkPJeUzvu
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Taking a break at the #ACR20? Visit https://t.co/KmscOUu8MO and access our online library of the the latest video abstracts, as well as extensive author interviews hosted by our editor. https://t.co/iRxroN2YWN
The Journal of Rheumatology jrheum ( View Tweet)
Can’t a clinician usually differentiate dermatomysitis skin changes from cutaneous lupus and if not would it affect your Rx of the skin involvement - HCQ, MMF, MTX, Aza & topicals. IL18 sigatures. But I get it. Impt for pathogenesis! @RheumNow #ACR2020 @CRASCRRheum https://t.co/RJh7fEVo4O
Janet Pope Janetbirdope ( View Tweet)
Are SpA response differences part of disease subsets or drug pharmacodynamics or both or neither? Data from COASTW & MEASURE2 @RheumNow #ACR2020 @CRASCRRheum https://t.co/GsFjZuZRvI
Janet Pope Janetbirdope ( View Tweet)
